文献速递肝病消化道肿瘤与早癌

抗菌凝集素REG3A靶向O-GlcNAc糖基化通路发挥肿瘤抑制作用

Tumor suppressive role of the antimicrobial lectin REG3A targeting the O -GlcNAc glycosylation pathway.
PubMed 文献 · Hepatology · 2024-07-02

本研究通过两种小鼠肝细胞癌模型、体外细胞实验和临床样本,证明REG3A在肝细胞中降低整体O-GlcNAc糖基化及c-MYC的O-GlcNAc糖基化,显著抑制肝细胞癌发生;肝硬化患者中肝REG3A高表达者O-GlcNAc糖基化水平更低、无癌生存期更长。

要点

  • REG3A在肝细胞中降低整体O-GlcNAc糖基化及c-MYC的O-GlcNAc糖基化。
  • REG3A抑制REG3A-c-MYC双转基因小鼠及二乙基亚硝胺暴露小鼠的肝细胞癌发生。
  • 肝硬化患者肝REG3A高表达与较低O-GlcNAc糖基化水平及较长无癌生存期相关。

核心结论

  • REG3A通过降低O-GlcNAc糖基化帮助对抗肝癌,提示通过REG3A的碳水化合物结合功能调控癌症相关通路中O-GlcNAc信号的新范式。

研究设计与样本

  • 研究采用两种小鼠肝细胞癌模型、体外细胞研究和临床样本,探究REG3A在肝癌发生中的作用及碳水化合物结合功能是否参与。

主要发现

  • 肝细胞中REG3A表达在癌前及肿瘤肝脏中显著降低整体O-GlcNAc糖基化及c-MYC的O-GlcNAc糖基化,并在REG3A-c-MYC双转基因小鼠和二乙基亚硝胺暴露小鼠中显著抑制肝细胞癌发展。
  • REG3A改变O-GlcNAc糖基化,而未改变O-linked N-acetylglucosaminyltransferase、O-linked N-acetylglucosaminyl hydrolase或glutamine fructose-6-phosphate amidotransferase的表达或活性。
  • O-GlcNAc糖基化降低与癌前及癌性肝脏中UDP-GlcNAc水平下降一致。
  • 该效应与REG3A结合葡萄糖和葡萄糖-6-磷酸的能力相关,依据为无法结合葡萄糖和葡萄糖-6-磷酸并改变O-GlcNAc糖基化的REG3A突变体。
  • 肝硬化患者中肝REG3A高表达者较REG3A阴性肝硬化肝脏者O-GlcNAc糖基化水平更低、无癌生存期更长。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Antimicrobial proteins of the regenerating family member 3 alpha (REG3A) family provide a first line of protection against infections and transformed cells. Their expression is inducible by inflammation, which makes their role in cancer biology less clear since an immune-inflammatory context may preexist or coexist with cancer, as occurs in HCC. The aim of this study is to clarify the role of REG3A in liver carcinogenesis and to determine whether its carbohydrate-binding functions are involved. APPROACH AND RESULTS: This study provides evidence for a suppressive role of REG3A in HCC by reducing O -GlcNAcylation in 2 mouse models of HCC, in vitro cell studies, and clinical samples. REG3A expression in hepatocytes significantly reduced global O -GlcNAcylation and O -GlcNAcylation of c-MYC in preneoplastic and tumor livers and markedly inhibited HCC development in REG3A-c-MYC double transgenic mice and mice exposed to diethylnitrosamine. REG3A modified O -GlcNAcylation without altering the expression or activity of O-linked N-acetylglucosaminyltransferase, O-linked N-acetylglucosaminyl hydrolase, or glutamine fructose-6-phosphate amidotransferase. Reduced O -GlcNAcylation was consistent with decreased levels of UDP-GlcNAc in precancerous and cancerous livers. This effect was linked to the ability of REG3A to bind glucose and glucose-6 phosphate, suggested by a REG3A mutant unable to bind glucose and glucose-6 phosphate and alter O -GlcNAcylation. Importantly, patients with cirrhosis with high hepatic REG3A expression had lower levels of O -GlcNAcylation and longer cancer-free survival than REG3A-negative cirrhotic livers. CONCLUSIONS: REG3A helps fight liver cancer by reducing O -GlcNAcylation. This study suggests a new paradigm for the regulation of O -GlcNAc signaling in cancer-related pathways through interactions with the carbohydrate-binding function of REG3A.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Moniaux N, Geoffre N, Deshayes A, et al. Tumor suppressive role of the antimicrobial lectin REG3A targeting the O -GlcNAc glycosylation pathway. Hepatology. 2024. PMID: 38975812. doi:10.1097/HEP.0000000000000993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。